Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Gains from Investment Securities: 2011-2025

Historic Gains from Investment Securities for Abeona Therapeutics (ABEO) over the last 8 years, with Sep 2025 value amounting to $394,921.

  • Abeona Therapeutics' Gains from Investment Securities rose 122.95% to $394,921 in Q3 2025 from the same period last year, while for Sep 2025 it was $394,921, marking a year-over-year increase of 122.95%. This contributed to the annual value of $584,700 for FY2024, which is 226.65% up from last year.
  • Abeona Therapeutics' Gains from Investment Securities amounted to $394,921 in Q3 2025, which was down 92.67% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Gains from Investment Securities registered a high of $8.6 million during Q2 2023, and its lowest value of -$24.9 million during Q2 2024.
  • For the 3-year period, Abeona Therapeutics' Gains from Investment Securities averaged around -$1.9 million, with its median value being $179,001 (2024).
  • Within the past 5 years, the most significant YoY rise in Abeona Therapeutics' Gains from Investment Securities was 6,165.00% (2022), while the steepest drop was 305,100.00% (2022).
  • Abeona Therapeutics' Gains from Investment Securities (Quarterly) stood at -$16,000 in 2021, then slumped by 33,575.00% to -$5.4 million in 2022, then skyrocketed by 178.51% to $4.2 million in 2023, then plummeted by 260.17% to -$6.8 million in 2024, then spiked by 122.95% to $394,921 in 2025.
  • Its Gains from Investment Securities was $394,921 in Q3 2025, compared to $5.4 million in Q2 2025 and -$7.2 million in Q1 2025.